Zanubrutinib
BGB-3111-LTE1
Phase 3 small_molecule active
Quick answer
Zanubrutinib for B-cell Malignancies is a Phase 3 program (small_molecule) at BeiGene with 2 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- B-cell Malignancies
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active